Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ozureprubart
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
**Ozureprubart** is a half-life extended monoclonal antibody designed to bind free human immunoglobulin E (IgE), inhibiting its interaction with receptors to suppress allergic responses in IgE-driven diseases. Developed by RAPT Therapeutics in collaboration with partners like Shanghai Jeyou Pharmaceutical and initially originated by Jemincare/Jiangsu Jiye Biopharmaceutical, it targets indications such as food allergy and chronic spontaneous urticaria (CSU), with potential expansion to asthma and other allergic conditions. It offers improved pharmacokinetics over omalizumab, enabling subcutaneous dosing every 8-12 weeks, and has shown comparable efficacy and safety in Phase 2 trials for CSU while advancing in Phase 2b for food allergies.[1][2][5][7]
- Other names
- Anti-immunoglobulin E antibody - Jemincare
02
Targets
IgE (Immunoglobulin E)
Beyond the preview
Go deeper on ozureprubart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ozureprubart.